

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: ENDRESS et al.

Application Serial No.: Not Assigned

Filed: Concurrently herewith

Title: Prostate Specific Secreted Protein

Group Art Unit: Not Assigned

Examiner: Not assigned

Atty. Docket No.: PF457D1



INFORMATION DISCLOSURE
STATEMENT PURSUANT TO 37 § CFR 1.56

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references AA-BD listed on the attached Form PTO/SB/08A.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR §§ 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Identification of the listed reference(s) is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Applicants respectfully request that the Examiner review the listed reference(s) and that the reference(s) be made of record in the file history of the application.


Pursuant to 37 C.F.R. § 1.97(b), since this information disclosure statement is being filed within three months of (i.e., concurrently with) the filing of the instant application, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Sciences, Inc., deposit account no. 08-3425.

Copies of references AA-BD were submitted by Applicants or cited by the Examiner in connection with U. S. Patent Application Serial No. 09/280,839, filed march 30, 1999, to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is (respectfully) directed to the above-listed files for copies of reference(s) AA-BD.

If any additional fees are deemed necessary, the Patent & Trademark Office is authorized to charge the required fee to Human Genome Sciences, Inc., Deposit Account No. 08-3425.

Respectfully submitted,

Dated: January 25, 2002


Jonathan L. Klein (Reg. No. 41,119)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Telephone: (301) 251-6015

JKE/JS/rmr

Please type a plus sign (+) inside this box ☐

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	Not assigned
				Filing Date	Concurrently herewith
				First Named Inventor	ENDRESS et al.
				Group Art Unit	Not assigned
				Examiner Name	Not assigned
Sheet	1	of	3	Attorney Docket Number	PF457D1

J0973 PTO
 10/05/97
 01/25/02

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (if known)	Kind Code ² (if known)			
	AA	4,544,545		Patrick J. Ryan et al.	10/1/1985	
	AB	6,022,847		Sheppard, P.O.	2/8/2000	
	AC	6,025,197		Sheppard, P.O.	2/15/2000	

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³ (known)	Number ⁴	Kind Code ⁵ (if known)		
	AD	WO	99/06550		2/11/1999	
	AE	WO	99/06548		2/11/1999	
	AF	WO	98/41628		9/24/1998	
	AG	WO	98/37418		8/27/1998	

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				T ⁶
	AH	Genbank Accession No. AA722847 (Jan-02-1998)				
	AI	Genbank Accession No. AA716150 (Dec-29-1997)				
	AJ	Genbank Accession No. AA577045 (Sep-03-1997)				
	AK	Genbank Accession No. AA559906 (Aug-18-1997)				
	AL	Genbank Accession No. AA533247 (Aug 18-1997)				
	AM	Genbank Accession No. AA367486 (Apr-21-1997)				
	AN	Genbank Accession No. AA340605 (Apr-21-1997)				

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ☐

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	Not assigned
				Filing Date	Concurrently herewith
				First Named Inventor	ENDRESS et al.
				Group Art Unit	Not assigned
				Examiner Name	Not assigned
Sheet	2	of	3	Attorney Docket Number	PF457D1

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (if known)	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³ (if known)	Number ⁴	Kind Code ⁵ (if known)			
	AO	WO	98/37093		8/27/1998		
	AP	WO	97/33902	Human Genome Sciences	9/18/1997		
	AQ	WO	99/40189		8/12/1999		
	AR	WO	99/58675	Chiron Corporation	11/18/1999		

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	
	AS	Amino acid database. Accession #U00964	
	AT	Krizman, David B. et al., "Construction of a Representative cDNA Library from Prostatic Intraepithelial Neoplasia". <i>Cancer Research</i> 56:5380-5383 (1996)	
	AU	Alberts, Bruce et al., <i>Molecular Biology of the Cell</i> , second edition. pp. 95-98 (1989)	
	AV	Biotechnology Industry Organization, "Critical Synergy: The Biotechnology Industry and Intellectual Property Protection", pp. 101, 103-104 (1994)	
	AW	Lin M. et al., "Structure-Function Relationships in Glucagon: Properties of Highly Purified Des-His (1), Monoiodo- and [Des-Asn (28), Thr (29)] (hormone lactose 27)-glucagon". <i>Biochemistry</i> 14(8):1559-1563 (1975)	
	AX	Schwartz et al., "A Superactive Insulin: [B10-Aspartic acid] insulin (human)", <i>Proc. Natl. Acad. Sci. USA.</i> (1987)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
	Application Number	Not assigned			
	Filing Date	Concurrently herewith			
	First Named Inventor	ENDRESS et al.			
	Group Art Unit	Not assigned			
	Examiner Name	Not assigned			
Sheet	3	of 3			
	Attorney Docket Number	PF457D1			

U.S. PATENT DOCUMENTS						
Examiner Initials [*]	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (if known) ³	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials [*]	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³ (known)	Number ⁴	Kind Code ⁵ (if known)			
	AY	WO	00/12708		Genentech, Inc.	3/09/2000	
	AZ	WO	00/05367		Sagami Chemical Research Center	2/03/2000	
	BA	WO	00/04149		Corixa Corporation	1/27/2000	

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	
	BB	Ricke, D.O. et al., GenBank Accession No. AC005361 (Aug-01-1998)	
	BC	NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap , Contact: Robert Strausberg Ph.D., GenBank Accession No. AI076929 (Aug-27-1998)	
	BD	NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap , Contact: Robert Strausberg Ph.D., GenBank Accession No. AI027322 (Aug-28-1998)	

Examiner Signature	Date Considered
-------------------------------	----------------------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.